ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 130,29
0,19%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Global Blood Therapeutics Inc (GBT)

  7. Global Blood Therapeutics Inc (GBT) Actualités

GBT

Global Blood Therapeutics (GBT)

Global Blood Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GBT
DateHeureSourceTitreSymboleSociété
09/02/202317h04Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GBTGlobal Blood Therapeutics Inc
17/10/202214h34Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:GBTGlobal Blood Therapeutics Inc
06/10/202222h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202222h41Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202222h33Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202222h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202215h00Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:GBTGlobal Blood Therapeutics Inc
16/09/202200h00GlobeNewswire Inc.GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022NASDAQ:GBTGlobal Blood Therapeutics Inc
12/09/202222h08Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:GBTGlobal Blood Therapeutics Inc
08/09/202214h00GlobeNewswire Inc.GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics ConferenceNASDAQ:GBTGlobal Blood Therapeutics Inc
29/08/202214h01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:GBTGlobal Blood Therapeutics Inc
09/08/202214h35TipRanksGlobal Blood Therapeutics (GBT) was downgraded to a Hold Rating at SVB SecuritiesNASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202213h29Dow Jones NewsGlobal Blood Therapeutics Shares Rise Premarket After Pfizer DealNASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202213h02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202212h45GlobeNewswire Inc.Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare HematologyNASDAQ:GBTGlobal Blood Therapeutics Inc
04/08/202222h05GlobeNewswire Inc.GBT Announces New Employment Inducement GrantsNASDAQ:GBTGlobal Blood Therapeutics Inc
03/08/202223h46Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:GBTGlobal Blood Therapeutics Inc
03/08/202222h05GlobeNewswire Inc.GBT Announces Participation at the Wedbush PacGrow Healthcare ConferenceNASDAQ:GBTGlobal Blood Therapeutics Inc
29/07/202214h00GlobeNewswire Inc.GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022NASDAQ:GBTGlobal Blood Therapeutics Inc
26/07/202209h01GlobeNewswire Inc.MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and OlderNASDAQ:GBTGlobal Blood Therapeutics Inc
14/07/202214h00GlobeNewswire Inc.GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in BrazilNASDAQ:GBTGlobal Blood Therapeutics Inc
13/07/202214h00GlobeNewswire Inc.The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based OrganizationsNASDAQ:GBTGlobal Blood Therapeutics Inc
09/07/202204h10TipRanksRBC Capital Keeps a Buy Rating on Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/07/202211h08TipRanksWilliam Blair Sticks to Its Buy Rating for Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
29/06/202218h55TipRanksWedbush Reiterates a Buy Rating on Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
29/06/202214h00GlobeNewswire Inc.GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
17/06/202222h05Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:GBTGlobal Blood Therapeutics Inc
16/06/202214h00GlobeNewswire Inc.NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
13/06/202214h00GlobeNewswire Inc.New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
13/06/202212h45TipRanksWedbush Thinks Global Blood Therapeutics’ Stock is Going to RecoverNASDAQ:GBTGlobal Blood Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GBT

Dernières Valeurs Consultées

EU
ML
Michelin
USI
USTECH100
US Tech 100
NASDAQ
NVDA
NVIDIA
EU
ACA
Credit Agricole
EU
AI
Air Liquide
NASDAQ
AAPL
Apple
EU
HO
Thales
EU
PX4
SBF 120
EU
DG
Vinci
NASDAQ
MSFT
Microsoft
EU
SGO
Cie de SaintGobain
COIN
ETHUSD
Ethereum
EU
AF
Air FranceKLM
EU
EN
Bouygues
NYSE
JPM
JP Morgan Chase
EU
CS
Axa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés